For clinical and preclinical teams
Request a sample-feasibility review
Before you commit samples or budget, find out what your existing plasma or serum can tell you. Send a few details about your study and the NeuroDex team will review whether brain-derived biomarkers fit your question and what your banked samples can support.
What you get back
- Which panels fit your target and question: TDP-43, α-synuclein, tau/pTau, Akt pathway, NfL, GFAP, p-Tau217 or a custom assay
- Whether your sample volumes and storage are suitable (500 µL EDTA plasma or serum per sample)
- A suggested pilot design on samples you already have
- Expected turnaround, typically 2–3 weeks from sample receipt
Helpful to include in your message
- Target or pathway, and disease area
- Sample type, volume per sample and number of samples
- Number of visits or timepoints
- Study stage: preclinical, Phase 1, Phase 2
40+ pharma and biotech collaborationsRegistered primary outcome in a Phase 2b ALS trialMore than 50-fold neuronal signal vs plasma
Background reading: Before you add a blood biomarker to your trial, test it on samples you already have.

